Day: June 2, 2025

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma’s apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase Ib/II study of the investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with hypomethylating agent azacitidine in patients with treatment-naïve (TN) or prior venetoclax-exposed myeloid malignancies, in an oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community. As Ascentage Pharma returns...

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Nxera previously announced the initiation of the Phase 3 registrational program of NBI-’568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-’568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll...

BOCA RATON, FL, June 02, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a record-setting May 2025 highlighted by significant advancements across its validator infrastructure, treasury growth, and strategic integrations. Key May 2025 Highlights:Record SOL Purchases: DeFi Dev Corp. achieved its largest monthly SOL purchase, reinforcing its strategy to build the world’s leading publicly traded Solana treasury.Validator Launches: The Company announced a validator partnership with Bonk, Solana’s largest memecoin community, adding to its expanding network of revenue-generating validators.Kamino Integration: DeFi Dev Corp. signed a letter of intent with Kamino Finance,...

Taipei, Taiwan, June 02, 2025 (GLOBE NEWSWIRE) — Semilux International Ltd. (NASDAQ:SELX) (“SELX” or the “Company”) announced that it received a delinquency notification letter on May 27, 2025 (the “Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”) notifying the Company that it is no longer in compliance with the Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) for continued listing due to its failure to timely file its annual report on Form 20-F for the year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. In accordance with Nasdaq’s listing rules, the Company has 60 calendar days after the Deficiency Letter to...

VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company’s board of directors (the “Board”) at the Meeting and listed in the Company’s Management Information Circular dated April 25, 2025, were elected. The directors will remain in office until the next annual meeting of shareholders, or until their successors are...

CALGARY, Alberta, June 02, 2025 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce the appointment of Alberto Consuegra to the Board of Directors (the “Board”). Effective June 1, 2025, Alberto Consuegra has been appointed to the Board as an independent director. Alberto has more than 30 years of experience in the energy sector. Most recently, Mr. Consuegra served as the Chief Operating Officer of Ecopetrol, Colombia’s national oil company, and for a period of time acted as the Company’s interim Chief Executive Officer. He has also served as the President of Cenit Transporte y Logística de Hidrocarburos S.A.S., the Vice President of Supply and Services of Ecopetrol, and held several executive positions at Equion Energia Ltd. and BP Exploration. Mr. Consuegra graduated from Universidad...

SYDNEY, June 02, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Mark Gossington as a Senior Managing Director in the Risk & Investigations practice within the firm’s Forensic and Litigation Consulting segment. Mr. Gossington, who is based in Sydney, brings more than 25 years of experience leading complex risk engagements and remediation programmes that have helped companies strengthen resilience under regulatory scrutiny, recover from misconduct issues and build compliance frameworks that stand up to enforcement and market shifts. He has expertise across UK and Australian regulatory requirements, compliance obligations and risk management frameworks. In his role at FTI Consulting, he will focus on helping financial services clients in Australia and the Asia Pacific region navigate...

– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically meaningful QTc prolongation; 3% of patients discontinued due to treatment-related adverse events – – Potential first approval of a once-daily, oral menin inhibitor for treatment of adult patients with relapsed or refractory NPM1-mutated AML with Priority Review and a PDUFA target action date of November 30, 2025 – – Kura Oncology to host virtual investor event today at 7:30pm ET / 4:30pm PT – SAN DIEGO and TOKYO, June 02, 2025 (GLOBE NEWSWIRE) —...

Basildon, June 2, 2025 CNH Industrial N.V. (NYSE: CNH) today announced that its indirect wholly owned subsidiary, CNH Industrial Capital Canada Ltd., has priced Cdn$500 million in aggregate principal amount of 3.75% notes due June 5, 2029, with an issue price of 100.00%. The notes are being offered on a private placement basis to certain accredited investors in each of the provinces of Canada, which offering is expected to close on June 5, 2025, subject to the satisfaction of customary closing conditions. CNH Industrial Capital Canada Ltd. intends to add the net proceeds from the offering to its general funds and use them for working capital and other general corporate purposes, including, among other things, the purchase of receivables or other assets in the ordinary course of business, as well as the repayment of indebtedness as it becomes...